Since the publication of the first study showing efficacy of low-dose subcutaneous IL-2 therapy in the treatment of hepatitis C-induced vasculitis [82] and graft-versus-host disease (GvHD) [83], this treatment has appeared in more than 30 different autoimmune and inflammatory disease studies and clinical trials. This evidence concerns the gene IL2 and vasculitis.